Abstract
Introduction

44
Acute respiratory distress syndrome (ARDS) is a severe clinical condition that is associated 45 with impaired alveolar-capillary barrier permeability leading to formation of protein-rich 46 edema and compromised alveolar gas exchange (50). The therapy of ARDS remains entirely supportive and no pharmacological means exist (23). It is very well established that the fraction) and the pellets were resuspended in 0.1% Triton X-100 in PBS prior to 217 centrifugation at 10,000 x g for 5 min. Supernatants were collected (taken up fraction).
218
Fluorescence was measured by duplicates with an ELISA reader setting excitation at 490 nm 219 and emission: 520 nm. Total amounts of proteins were measured from the taken up fraction 220 by Bradford assay and used for normalization of fluorescence values.
221
Statistical analysis. All data sets were plotted as mean ± standard error of the mean (SEM).
222
For statistical analysis and plotting of the data, GraphPad Prism 5 for Windows software was groups were done by one-or two-way ANOVA and Tukey's or Šidák's multiple comparisons 227 or Dunnett's multiple comparisons when each group was compared to a control group.
228
Statistical significance was defined as *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
230
Results
231
TGF-β-induced release of megalin intracellular domain reduces gene expression and cell
232
surface stability of megalin. In order to study whether TGF-β regulates megalin expression, 233 we first evaluated mRNA expression of megalin 24 and 48 h after TGF-β treatment and 234 observed a significant downregulation in both RLE-6TN and primary rat ATII cells (Fig. 1A   235 and B, respectively). It has been previously suggested that in response to certain stimuli 236 megalin may be shed from the plasma membrane initiating a signaling cascade that by 237 promoting RIP leads to the release of the megalin intracellular domain (MICD), which may 238 translocate into the nucleus and specifically downregulate gene expression of megalin (3, 32, 239 33). In order to study whether MICD release is regulated by TGF-β, we next measured the abundance of the MICD precursor, MCTF (megalin c-terminal fragment) in whole cell 241 homogenates from RLE-6TN cells (detection of MICD was not feasible due to its very short 242 half-life) and detected a time-dependent increase in intracellular MCTF abundance 4 to 24 h 243 after TGF-β treatment, showing a maximum between 8 and 12 h after TGF-β exposure (Fig. 244 1C). To establish a link between the TGF-β-induced MICD release and downregulation of 245 megalin expression, we next measured gene expression of the sodium/proton exchanger 246 channel 3 (NHE3), which has previously been described to be a target of MICD (32) , in the 247 presence or absence of TGF-β or synthetic MICD for 24 h. A significant reduction of megalin 248 mRNA levels was seen both in RLE-6TN and ATII cells when treated either with TGF-β or 249 synthetic MICD, however, the effect of TGF-β treatment on NHE3 expression was less 250 prominent ( Fig. 2A and B ). Considering that synthetic MICD was added in excess and that it 251 targets the pathway clearly downstream of TGF-β, we next asked whether this unexpected 252 lack of effect of TGF-β on NHE3 gene expression was due to an insufficient time of TGF-β 253 exposure. To answer this question, we repeated these measurements 48 h after TGF-β 254 treatment and detected a significant downregulation of NHE3 expression in both cell types
255
( Fig. 2C and 2D ). Collectively, these results suggest that TGF-β may exert an effect on 256 megalin downregulation by inducing release of MICD into the cytoplasm, which may 257 subsequently translocate into the nucleus and inhibit gene expression of megalin.
258
In order to further characterize the effects of MICD on megalin downregulation, we evaluated 259 the cell surface stability of megalin in the presence or absence of synthetic MICD and TGF-β was detected) by applying streptavidin pulldown assays. Of note, exogenous MICD reduced 262 megalin cell surface stability markedly and comparably to TGF-β treatment in both RLE-6TN 263 and ATII cells ( Fig. 3A and B) . Importantly, both treatments also significantly reduced 264 megalin mRNA levels after 10 h of exposure (Fig. 3C ). Considering that albumin is the most 265 abundant protein in plasma that can bind to megalin, binding and uptake of FITC-albumin were also measured in order to test the function of cell surface megalin in the presence or absence of MICD or TGF-β. RLE-6TN or ATII cells were treated as described above and 268 subsequently incubated with FITC-albumin for 1 h. Receptor-bound and taken up fractions 269 were collected and fluorescence intensity was measured. Consistently with the effects of 270 MICD and TGF-β on megalin cell surface abundance, both binding and uptake of FITC-271 albumin showed a reduction when RLE-6TN or ATII cells were treated with either MICD or 272 TGF-β ( Fig. 3D and E) . These effects, albeit significant, were not as pronounced as the effects clearance, we repeated the above mentioned experiments after silencing the expression of 278 megalin. In line with our previous findings, the effects of both MICD and TGF-β treatments 279 were lost after megalin knockdown (Fig. 3F) . Additionally, binding and uptake of FITC-280 albumin were reduced to approx. 50% of control levels. Collectively, these data suggest that 281 the clearance of the bulk of total albumin across alveolar epithelial cells requires megalin 282 function and MICD and TGF-β impair albumin transport by inhibiting megalin. Controls of 283 specificity of albumin transport were performed with 70 kDa FITC-dextran, which has a 284 similar molecular weight as albumin but is not actively transported across the alveolar 285 epithelium (Fig. 3G ) (6).
286
TGF-β-induced megalin downregulation requires PKC and γ-secretase activity. As it has 287 been previously reported that shedding and RIP of megalin in other cell types are dependent 288 on activities of PKC and γ-secretase and that the regulation of these two processes determines 289 the intracellular amounts of MCTF and MICD (3, 32), we next investigated the potential 290 regulatory role of TGF-β in these processes by specific knockdown (KD) of the enzymes.
291
RLE-6TN cells were transfected with siRNA against PS-1, an enzyme responsible for the γ-secretase activity in the proteolytic complex, and megalin cell surface stability was evaluated 293 after 10 h of TGF-β treatment (a time point where maximum intracellular abundance of 294 MCTF was detected). Indeed, silencing PS-1 abolished the TGF-β-induced impairment of 295 megalin cell surface stability (Fig. 4A) . Similar data on TGF-β-induced reduction of megalin 296 cell surface expression and activity were obtained after silencing PKCα/β ( Fig. 4B and C) .
297
Furthermore, specific KD of PS-1 also prevented the negative effects of TGF-β on megalin- MMP-2 and MMP-14 protein levels in the first 4 h after treatment, an enhanced protein expression of MMP-9 was evident 12 h after TGF-β exposure (Fig. 6A-C 
322
To further test our hypothesis, we measured the effects of TGF-β on MMP-2 and MMP-9 323 exocytosis by a specific ELISA from cell culture supernatants using the same time course as Because MMP-14 remains attached to the cell surface, it is not feasible to detect this protease 341 in cell culture supernatants. Therefore, we studied MMP-14 translocation to the plasma 342 membrane after treatment with TGF-β. RLE-6TN cells were exposed to TGF-β for 10 h and the plasma membrane fraction was purified from whole cell lysates. Of note, we observed a 344 translocation of MMP-14 into the plasma membrane fraction after TGF-β exposure (Fig. 8A ), 345 which was confirmed by immunofluorescence and confocal microscopy ( Fig. 9 ).
346
Interestingly, we also detected an increased abundance of MMP-9 and PKC-α and -β at the 347 cell surface (Fig. 8A) , suggesting that TGF-β may promote translocation of these proteins to 348 the plasma membrane, although exocytosis and extracellular activation of MMP-9 were not 
MMP-2 and MMP-14 physically interact with megalin at the plasma membrane in presence of
356
TGF-β. As we found that MMP-2 and -14 activities were upregulated by TGF-β and
357
considering that physical interaction of proteins might be necessary for proteolysis, we 358 studied the potential interaction of MMP-2 and -14 with megalin by co-immunoprecipitation 359 (co-IP) assays from plasma-membrane-enriched fractions after 10 h of treatment with TGF-β.
360
As shown in Fig. 10A and B, both MMP-2 and MMP-14 were pulled down with megalin 361 when specific antibodies for the receptor were used for IP. Importantly, reverse co-IPs (in 362 which MMP-2 or MMP-14 were immunoprecipitated) also pulled down megalin ( acute lung injury (6, 27, 28, 49, 55) . Indeed, in intact, isolated, ventilated and perfused rabbit 406 lungs, we observed that the velocity of active albumin clearance is high and can be markedly 407 attenuated by reducing temperature, by competition or by inhibitors of endocytosis (6). In the present study we show that TGF-β upregulates total protein expression of MMP-2 and -489 9 after 4 h of treatment in alveolar epithelial cells. Of note, a correlation between MMP-2 490 levels and megalin ectodomain release into the extracellular space was found as well.
491
Consistently with our findings, even if both MMP-2 and -9 have been reported to be highly processing, thereby leading to its activation (22, 31, 37) . In the present study, we describe a 534 novel regulatory mechanism of protein clearance from the alveolar space. Elevated levels of 
